| abstract |
A treatment for bone marrow suppression is provided. Methods are provided for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing the effectiveness of treatment regimens by administering PF4 interacting heparinoids. ing. In a first aspect, a method is provided for attenuating myelosuppressive side effects of a patient treatment regimen. The method includes the step of supplementally administering to the patient a therapeutically effective amount of a platelet factor 4 interacting heparinoid (hereinafter “PF4 interacting heparinoid”). As presented herein, myelosuppressive side effects are the occurrence of thrombocytopenia and / or neutropenia, and patient treatment regimens with myelosuppressive side effects include thrombocytopenia and A treatment regimen that induces one or both of neutropenia. [Selection figure] None |